Tarsus Pharmaceuticals, Inc. announced topline results from the Ersa Phase 2a clinical trial evaluating TP-03 administered twice daily or three times a day for 12 weeks for the treatment of Meibomian.
Clarus Therapeutics (OTCMKTS:CRXTQ – Get Free Report) and Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations. Analyst Recommendations This is a breakdown of current […]
Celebrating Seeking Alpha s New Analysts - November 2023 Edition seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.